Argen-X (ARGX.BR) — the peer cohort

As of 2026-09-18 — scores re-bake nightly. Cohort = shared Closelook index membership first, then sector. Diary readings, not advice.

Argen-X ranks 2 of 7 in its cohort on the Closelook composite (65/100) — the cohort is led by BB Biotech AG at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
ARGX.BR Argen-X 65 79 75 28 ok 5.8%
BION.SW BB Biotech AG 74 74 96 81 info 8.2%
ARGX argenx NV ADR 64 79 74 27 ok 7.7%
ONC BeiGene, Ltd. 63 75 63 32 ok 8.9%
REGN Regeneron Pharmaceuticals Inc 60 64 71 51 bull 8.1%
UCB.BR UCB SA 60 17 70 58 warn 27.8%
CAI Caris Life Sciences, Inc. Common Stock 59 73 60 31 ok 13.2%

Scores are relative readings across the Closelook coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-09-18

Quick answers

Who are Argen-X's peers in the Closelook universe?

The cohort is drawn from shared Closelook index membership first, then sector: BB Biotech AG (BION.SW), argenx NV ADR (ARGX), BeiGene, Ltd. (ONC), Regeneron Pharmaceuticals Inc (REGN), UCB SA (UCB.BR), Caris Life Sciences, Inc. Common Stock (CAI).

How does ARGX.BR score against its peers?

Argen-X's composite reads 65/100, ranking 2 of 7 in its cohort as of 2026-09-18; the cohort's highest composite is BB Biotech AG at 74/100. Closelook scores are research diary readings, not ratings or advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.